259 related articles for article (PubMed ID: 34320421)
1. Real-world insights into patients with advanced NSCLC and MET alterations.
Bittoni M; Yang JC; Shih JY; Peled N; Smit EF; Camidge DR; Arasada RR; Oksen D; Boutmy E; Stroh C; Johne A; Carbone DP; Paik PK
Lung Cancer; 2021 Sep; 159():96-106. PubMed ID: 34320421
[TBL] [Abstract][Full Text] [Related]
2. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
3. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy.
Kron A; Scheffler M; Heydt C; Ruge L; Schaepers C; Eisert AK; Merkelbach-Bruse S; Riedel R; Nogova L; Fischer RN; Michels S; Abdulla DSY; Koleczko S; Fassunke J; Schultheis AM; Kron F; Ueckeroth F; Wessling G; Sueptitz J; Beckers F; Braess J; Panse J; Grohé C; Hamm M; Kabitz HJ; Kambartel K; Kaminsky B; Krueger S; Schulte C; Lorenz J; Lorenzen J; Meister W; Meyer A; Kappes J; Reinmuth N; Schaaf B; Schulte W; Serke M; Buettner R; Wolf J
J Thorac Oncol; 2021 Apr; 16(4):572-582. PubMed ID: 33309988
[TBL] [Abstract][Full Text] [Related]
4. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
5. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Wolf J; Souquet PJ; Goto K; Cortot A; Baik C; Heist R; Kim TM; Han JY; Neal JW; Mansfield AS; Gilloteau I; Nwana N; Waldron-Lynch M; Davis KL; Giovannini M; Awad MM
Clin Lung Cancer; 2023 Nov; 24(7):641-650.e2. PubMed ID: 37741716
[TBL] [Abstract][Full Text] [Related]
6. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
[TBL] [Abstract][Full Text] [Related]
8. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
9. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
10. Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.
Skribek M; Brunnström H; Oskarsdottir G; Portu Grivé M; Aricak O; Planck M; Jatta K; Naserhojati H; Haglund de Flon F; Ekman S
Acta Oncol; 2023 Dec; 62(12):1808-1814. PubMed ID: 37897706
[TBL] [Abstract][Full Text] [Related]
11. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
Mazieres J; Paik PK; Garassino MC; Le X; Sakai H; Veillon R; Smit EF; Cortot AB; Raskin J; Viteri S; Wu YL; Yang JCH; Ahn MJ; Ma R; Zhao J; O'Brate A; Berghoff K; Bruns R; Otto G; Johne A; Felip E; Thomas M
JAMA Oncol; 2023 Sep; 9(9):1260-1266. PubMed ID: 37270698
[TBL] [Abstract][Full Text] [Related]
12. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
13. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
14. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
17. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Pruis MA; Krebs MG; Plummer R; De Vos F; Angevin E; Prenen H; Forster MD; Clack G; Van der Aa A; Tjwa M; Jansen E; Perera T; Lolkema MP
Oncologist; 2023 Dec; 28(12):e1248-e1258. PubMed ID: 37260332
[TBL] [Abstract][Full Text] [Related]
19. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.
Peng KC; Su JW; Xie Z; Wang HM; Fang MM; Li WF; Chen YQ; Guan XH; Su J; Yan HH; Zhang XC; Tu HY; Zhou Q; Chen HJ; Wu YL; Yang JJ
Thorac Cancer; 2022 Jun; 13(11):1619-1630. PubMed ID: 35437920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]